Sort by
Refine Your Search
-
Category
-
Program
-
Field
-
, influences the tumor immuno-environment and synergizes with anti-cancer immunotherapies. These approaches will be complemented with the generation of novel recombinant antibodies targeting specific
-
physician orders and established policies and procedures. RNs with no previous oncology/chemo experience will be skilled to administer chemotherapy/immunotherapy within 6-8 months of hire. We offer didactic
-
to administer chemotherapy/immunotherapy within 6-8 months of hire. We offer didactic education and hands-on precepted orientation for chemotherapy/immunotherapy administration based on ONS/APHON guidelines, DUHS
-
the lab. Responsible for processing freshly resected tumors and autologous PBMCs from patients with cancer. Handle live mice to perform treatments testing specific immunotherapies, delivered through
-
. This candidate will work alongside a talented team of research technicians and analysts. Primary Responsibilities Design and execute project plans to evaluate therapeutic efficacies of combination immunotherapy
-
metabolic pathways in mediating resistance to immunotherapy. We leverage clinical trials and patient samples as the cornerstone of our research and every endeavor in our lab is geared towards improving
-
administer chemotherapy, immunotherapy agents, and research medications via different routes of administration including intravenous, oral, subcutaneous, intrathecal, intraperitoneal, intravesicular, and
-
of researchers and clinicians, you will have the opportunity to work with cutting-edge technology and techniques to study the innate immune system, the impact of immunotherapy treatment and delivery of drugs in
-
administer chemotherapy, immunotherapy agents, and research medications via different routes of administration including intravenous, oral, subcutaneous, intrathecal, intraperitoneal, intravesicular, and
-
resistance to immunotherapy. We leverage patient samples as the cornerstone of our research and every endeavor in our lab is geared towards improving clinical outcomes for cancer patients. We are developing a